Imv Inc
IMV Inc. operates as a clinical-stage immuno-oncology company. Its lead candidate is DPX-Survivac, which is in Phase II trial for the treatment of recurrent ovarian cancer, as well as in Phase I/II trial for the treatment of advanced cancers; and developing a combination therapy regimen with checkpoint inhibitor. The company's product candidates also include DPX-E7, which is in Phase I/II trial for the treatment of human papillomavirus associated cancers; and DIANOVA for the treatment of solid tumors. In addition, it is developing DPX-RSV that has completed preclinical trials for used in lung cancer; and DPX-COPD vaccine to treat chronic obstructive pulmonary disease. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Latest events on Quartr
Previous Events for Imv Inc
Ticker
IMV
Country
United States of America
About the company
https://www.imv-inc.com/about-us
Investor Relations page
Dig deeper into the fundamentals using Quartr - Investor relations
- Skip straight to the Q&A session
- Receive notifications about new events
- Connect the financial calender on your phone
- Figure out why the stock is up or down
- Read the transcripts or scroll the deck
- Access earnings or press releases
